METTL3-Mediated N6-Methyladenosine Ferroptosis in Sepsis-Associated Acute Lung Injury - A Narrative Review

Sepsis-induced acute lung injury (ALI) represents a complex and life-threatening condition with limited therapeutic options. Recent research has unveiled the role of methyltransferase-like 3 (METTL3)-mediated N6-methyladenosine (m6A) modifications in exacerbating ferroptosis via m6A-insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2)-dependent mitochondrial metabolic reprogramming, shedding light on potential therapeutic targets. This study delves into the implications, challenges, and prospects of this intricate molecular pathway in sepsis-associated ALI. METTL3-mediated M6A modifications assume a pivotal role in the pathogenesis of sepsis-induced ALI. These modifications exacerbate ferroptosis, a regulated cell death process characterized by iron-dependent oxidative damage to lipids. The involvement of m6A-IGF2BP2-dependent mitochondrial metabolic reprogramming adds another layer of complexity to this mechanism, offering potential therapeutic avenues. Understanding the intricate network of METTL3-mediated m6A modifications, IGF2BP2, and mitochondrial metabolic reprogramming poses a formidable challenge. Developing interventions that modulate this pathway while minimizing off-target effects remains a significant hurdle. Patient-specific responses and identifying reliable biomarkers further complicate the clinical translation of these findings. The unraveling of this molecular pathway holds promise for personalized medicine approaches in ALI management. Early diagnosis and tailored interventions based on individual patient profiles may significantly enhance clinical outcomes. Collaboration among multidisciplinary teams, including researchers, clinicians, and drug developers, is essential to bridge the gap between laboratory discoveries and clinical applications.